Lmcg Investments LLC Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lmcg Investments LLC lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,371 shares of the biopharmaceutical company’s stock after selling 453 shares during the period. Lmcg Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $3,114,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $37,000. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $42,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 1.7 %

Shares of REGN stock opened at $681.58 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business has a 50-day moving average of $738.60 and a 200 day moving average of $948.80. The stock has a market capitalization of $74.90 billion, a PE ratio of 16.87, a P/E/G ratio of 1.61 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20.

Analysts Set New Price Targets

REGN has been the subject of a number of recent analyst reports. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Leerink Partners restated a “market perform” rating and set a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.